European Medicines Agency Accepts MAA for Gout Drug
the Clinical Pain Advisor take:
The European Medicines Agency has accepted the Marketing Authorization Application (MAA) for lesinurad 200 mg tablets.
According to a press release from AstraZeneca, lesinurad is a selective uric acid reabsorption inhibitor (SURI) developed for the chronic treatment of hyperuricaemia in combination with xanthine oxidase (XO) inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted.
The MAA filing was based on data from three clinical trisl - the CLEAR1, CLEAR2 and CRYSTAL Phase 3 studies. CLEAR1 and CLEAR2 were 12-month, randomized placebo-controlled studies that evaluated the efficacy and safety of a once daily dose of lesinurad in combination with allopurinol versus allopurinol alone, in symptomatic gout patients not achieving target serum uric acid (sUA) levels on their current allopurinol therapy.
CRYSTAL was a year-long randomized, placebo-controlled study that evaluated the efficacy and safety of a once daily dose of lesinurad in combination with febuxostat compared to febuxostat alone in gout patients with tophi.
The combined therapies of lesinurad and an XO inhibitor provides a dual mechanism approach targeting both excretion and production of uric acid, according to the study results, which were published by Ardea Biosciences, a member of the AstraZeneca Group.
Gout is a painful form of inflammatory arthritis.
Clinical Pain Advisor Articles
- FDA Takes Steps to Reconcile Needs of Patients With Chronic Pain, Efforts to Curb Opioid Epidemic
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Stat Consult: Chronic Low Back Pain
- Opioid Misuse May Help Predict Alcohol Dependence Treatment Outcomes
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- To Improve Healthcare Policy, Congress Needs More Physicians
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- The Ethical Argument Against Publishing Medical Research: What Responsibility Do Journal Editors Have?
- Poll: Should Migraineurs Avoid Headache Triggers?